Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07812116) titled 'A Study to Investigate Efficacy and Safety of Duvakitug in Adult Participants With Moderate to Severe Hidradenitis Suppurativa' on Sept. 4.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Sanofi
Condition:
Hidradenitis
Intervention:
Drug: Duvakitug
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: October 13, 2026
Target Sample Size: 156
To know more, visit https://clinicaltrials.gov/study/NCT0...